Merck and Moderna present Phase 3 cancer vaccine data at ESMO26 amid Treasury proposal on China investment

Endpoints Weekly reporter Nicole DeFeudis writes from Madrid during the ESMO26 meeting. The most anticipated presentation was a Phase 3 study of a cancer vaccine jointly developed by Merck and Moderna.

The conference update highlighted the data readout, though specific efficacy or safety results were not disclosed in the brief summary.

Separately, the article notes a Treasury proposal that could limit U.S. investment in China, a policy move that may affect pharmaceutical financing and cross‑border collaborations.

The piece serves as a quick roundup of the conference highlights and the broader regulatory environment affecting the industry.